Brought to you by 
Series B round brings Aclaris $21mm
29 Oct 2014
Executive Summary
Dermatology start-up Aclaris Therapeutics Inc.’s Series B financing brought in $21mm. Series A backers including Vivo Ventures, Fidelity Biosciences, and Sofinnova Ventures joined. Aclaris says it has enough money to move lead topical candidate A101, now in Phase II for seborrheic keratosis, through NDA filing (BioMedTracker says A101 has a 24% chance of approval).
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Topical Delivery
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series B round brings Aclaris $21mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice